drugset
drugset / Trial / NCT03239223

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223 ↗

Phase 1 Completed 16 enrolled Antiva Biosciences
RandomizedSequentialTriple-blindTreatment

Summary

This study evaluates the use of topical ABI-1968 cream, in the treatment of cervical precancerous lesions in adult women.

Timeline

Start
2018-01-01
Primary completion
2018-10-30
Completion
2018-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ABI-1968 Unknown — Topical

Indications

cervical cancer cervical intraepithelial neoplasia grade 2/3 cervical squamous intraepithelial neoplasia human papilloma virus infection